nelfinavir has been researched along with Viremia in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (30.77) | 18.2507 |
2000's | 9 (69.23) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belohradsky, BH; Eberle, J; Funk, M; Gürtler, L; Hoffmann, F; Linde, R; Notheis, G; Petropoulou, T; Wintergerst, U | 1 |
Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
Cao, Y; Essunger, P; Ho, DD; Hurley, A; Markowitz, M; Perelson, AS; Saksela, K; Vesanen, M | 1 |
Delwart, EL; Markowitz, M; Neumann, A; Pan, H | 1 |
Diehl, V; Fätkenheuer, G; Hoetelmans, R; Reiser, M; Salzberger, B; Stiepel, A | 1 |
Elmadfa, I; Jilma, B; Parschalk, B; Pernerstorfer-Schoen, H; Schindl, A; Schindler, K; Thoeny-Lampert, S; Tschachler, E; Wunderer, K | 1 |
Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
Chieco-Bianchi, L; De Rossi, A; Del Mistro, A; Giaquinto, C; Zamarchi, R | 1 |
Carter, LM; Ellis, BA; Peters, BS; Wolstencroft, RA | 1 |
Busch, M; Hecht, FM; Kahn, J; Levy, JA; Martinez-Marino, B; Ong, JC; Stranford, SA | 1 |
Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
Belohradsky, BH; Eberle, J; Engelhorn, C; Funk, M; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
2 trial(s) available for nelfinavir and Viremia
Article | Year |
---|---|
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance.
Topics: Drug Resistance, Microbial; Genes, env; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Ritonavir; Viremia | 1998 |
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Topics: Adult; Anti-HIV Agents; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Outcome; Viral Load; Viremia | 1999 |
11 other study(ies) available for nelfinavir and Viremia
Article | Year |
---|---|
Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral; Time Factors; Treatment Refusal; Viral Load; Viremia | 2002 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
Decay characteristics of HIV-1-infected compartments during combination therapy.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Leukocytes, Mononuclear; Macrophages; Mathematics; Models, Biological; Nelfinavir; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonic Acids; Viral Load; Viremia; Virus Latency; Zidovudine | 1997 |
Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Basal Metabolism; Body Composition; Body Weight; Case-Control Studies; Cohort Studies; Didanosine; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Viremia | 1999 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child.
Topics: Anti-HIV Agents; Antibody Formation; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Antibodies; HIV Infections; HIV Seronegativity; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viremia; Zidovudine | 2000 |
Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Lymphocytes; Macrophage Inflammatory Proteins; Male; Nelfinavir; Stavudine; Viral Load; Viremia | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Depression, Chemical; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Immunity, Cellular; Indinavir; Lamivudine; Lymphocyte Count; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Refusal; Viral Load; Viremia; Zidovudine | 2001 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |
Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viremia | 2002 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |